Evidence map›Paper›PMID 42523407›Full record

ArticlebioRxiv : the preprint server for biology2026

Prototype-based AI triage for 3D pathology.

Renao Yan, Gan Gao, Andrew H Song, Huai-Ching Hsieh, Yujie Zhao, Cristina Almagro-Pérez, David Brenes, Sarah S L Chow, Jeanne Shen, Deepti M Reddi and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Renao YanDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.ORCID 0000-0002-2399-199X
Gan GaoDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.
Andrew H SongDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Huai-Ching HsiehDepartment of Pathology, Stanford University, Stanford, CA, USA.
Yujie ZhaoDepartment of Pathology, Stanford University, Stanford, CA, USA.
Cristina Almagro-PérezDepartment of Pathology, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
David BrenesDepartment of Pathology, Stanford University, Stanford, CA, USA.
Sarah S L ChowDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.
Jeanne ShenDepartment of Pathology, Stanford University, Stanford, CA, USA.
Deepti M ReddiDepartment of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA.
Lawrence D TrueDepartment of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA.
Priti LalPathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Anant MadabhushiWallace H. Coulter Department of Biomedical Engineering, Emory University & Georgia Institute of Technology, Atlanta, GA, USA.
Faisal MahmoodCancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Jonathan T C LiuDepartment of Mechanical Engineering, University of Washington, Seattle, WA, USA.

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
Whole Exome Approaches for Esophageal Adenocarcinoma Susceptibility GenesU54CA163060 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI CHAK, AMITABH, GUDA, KISHORE · 2011 to 2022
$14.0M
Identify and validate novel epigenetic molecular markers for colorectal neoplasmU01CA152756 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GRADY, WILLIAM MALLORY, GUDA, KISHORE · 2010 to 2021
$6.7M
Biomarkers for optimizing risk prediction and early detection of cancers of the colon and esophagusU2CCA271902 · NCI · FRED HUTCHINSON CANCER CENTER · PI Cecilia C Yeung · 2022 to 2026
$5.3M
Pathology CoreU54CA254566 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MADABHUSHI, ANANT · 2020 to 2024
$5.0M
Esophageal Cancer from Cells to Population: A Multiscale ApproachU01CA182940 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HUR, CHIN, INADOMI, JOHN MATTHEW · 2013 to 2017
$3.3M
(PQ6) Radiogenomics of colorectal polyps to assess benign proliferative vs. premalignant states.R01CA220004 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GRADY, WILLIAM MALLORY, HALBERG, RICHARD BROTT · 2017 to 2021
$3.2M
Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)R01CA249992 · NCI · EMORY UNIVERSITY · PI LEWIS, JAMES, MADABHUSHI, ANANT · 2021 to 2025
$3.2M
Computerized histologic image predictor of cancer outcomeR01CA202752 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FELDMAN, MICHAEL D, GANESAN, SHRIDAR · 2016 to 2020
$3.1M
Prostate cancer risk stratification via computational 3D pathologyR01CA268207 · NCI · UNIVERSITY OF WASHINGTON · PI Jonathan T.C. Liu, Anant Madabhushi · 2022 to 2026
$3.1M
Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal CarcinomaR01CA220581 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KOYFMAN, SHLOMO, LEWIS, JAMES · 2018 to 2023
$3.1M
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersR01CA216579 · NCI · EMORY UNIVERSITY · PI FU, PINGFU, LLOYD, MARK · 2018 to 2023
$3.1M
BLRD VA I01 BX004121BLRD VA IK6 BX006185NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA202752NCI NIH HHS R01 CA208236NCI NIH HHS R01 CA216579NCI NIH HHS R01 CA220004NCI NIH HHS R01 CA220581NCI NIH HHS R01 CA249992NCI NIH HHS R01 CA257612NCI NIH HHS R01 CA268207NCI NIH HHS R01 CA268287NCI NIH HHS R01 CA270437NCI NIH HHS U01 CA152756NCI NIH HHS U01 CA182940NCI NIH HHS U01 CA239055NCI NIH HHS U01 CA248226NCI NIH HHS U01 CA269181NCI NIH HHS U2C CA271902NCI NIH HHS U54 CA163060NCI NIH HHS U54 CA254566NIBIB NIH HHS R01 EB031002NIDDK NIH HHS R01 DK138948
6 · The paper itself

Abstract

Non-destructive 3D pathology enables high-resolution slide-free imaging of intact clinical specimens, providing comprehensive visualization of tissue structures beyond what conventional slide-based 2D histopathology can provide. However, the scale and complexity of volumetric datasets make exhaustive manual review impractical, motivating AI-assisted triage methods to select a small number of high-risk 2D slices for pathologist review. While prior triage models have shown promise, interpretability is poor and performance can be suboptimal, especially in the nascent field of 3D pathology in which labeled data is limited. We present SCOPE, a

Identifiers

PMID42523407
PMCPMC13405288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.